After 6 and 12 weeks of induction therapy, there was an improvement in anemia and thrombocytopenia, normalization of albumin levels, decrease in C-reactive protein (CRP) to normal levels, improvement in hepatosplenomegaly, and a reduction in bone lesions. The gene discussed is CRP; the disease is anemia (phenotype).